Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Farmers Insurance
Chinese Patent Office
Boehringer Ingelheim
Mallinckrodt
Novartis
Queensland Health
Federal Trade Commission
Medtronic
Argus Health

Generated: December 11, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,932,268

« Back to Dashboard

Which drugs does patent 7,932,268 protect, and when does it expire?


Patent 7,932,268 protects JUXTAPID and is included in one NDA.

This patent has twenty-four patent family members in sixteen countries.

Summary for Patent: 7,932,268

Title:Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects
Abstract: The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.
Inventor(s): Rader; Daniel J. (Philadelphia, PA)
Assignee: The Trustees of the University of Pennsylvania (Philadelphia, PA)
Application Number:10/591,923
Patent Claim Types:
see list of patent claims
Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-001Dec 21, 2012RXYesNo► Subscribe► Subscribe► SubscribeA DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-002Dec 21, 2012RXYesNo► Subscribe► Subscribe► SubscribeA DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-003Dec 21, 2012RXYesNo► Subscribe► Subscribe► SubscribeA DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-004Apr 23, 2015RXYesNo► Subscribe► Subscribe► SubscribeA DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-005Apr 23, 2015RXYesNo► Subscribe► Subscribe► SubscribeA DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
AegerionJUXTAPIDlomitapide mesylateCAPSULE;ORAL203858-006Apr 23, 2015RXYesYes► Subscribe► Subscribe► SubscribeA DOSING REGIMEN FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND HYPERLIPIDEMIA IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA USING AT LEAST THREE STEP-WISE INCREASING DOSES
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 7,932,268

PCT Information
PCT FiledMarch 07, 2005PCT Application Number:PCT/US2005/007435
PCT Publication Date:September 22, 2005PCT Publication Number: WO2005/087234

Non-Orange Book Patents for Patent: 7,932,268

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,618,135Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects► Subscribe
9,433,617Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects► Subscribe
9,364,470Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects► Subscribe
9,265,758Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,932,268

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
SloveniaEP1725234► Subscribe
Serbia52825► Subscribe
Portugal1725234► Subscribe
New Zealand549721► Subscribe
Netherlands300634► Subscribe
LithuaniaC1725234► Subscribe
South Korea20060129082► Subscribe
South Korea101494067► Subscribe
South Korea20130004942► Subscribe
Japan2012232995► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Daiichi Sankyo
Healthtrust
Cipla
Colorcon
Dow
Cerilliant
Baxter
Merck
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot